News in brief: Nexalis advances IRX-616a and IRX-211 programs; Vitura heralds Doctors on Demand growth; Elixinol improves cash flow by Adam Sheldon April 20, 2026April 22, 2026 Nexalis Therapeutics – formerly InhaleRx – has completed dosing in the first cohort of its Phase […]
Elixinol names new chair in pursuit of ‘sustainable and profitable business’ by Steve Jones December 2, 2025February 21, 2026
Cannabis executive salaries: who earned what in FY25 by Adam Sheldon October 22, 2025October 22, 2025
Elixinol Wellness secures A$2.5m to fund ‘reset strategy’ by Adam Sheldon September 8, 2025February 21, 2026
News in brief: Elixinol names new CEO; Aurora flags MedReleaf growth; InhaleRx R&D tax rebate; ODC to ‘share insights’; Tilray appoints new Australian director by Steve Jones June 20, 2025June 26, 2025
